Clinical trials: Hemorrhagic Complications
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT, CHROMOSOME 2q31.2 DELETION SYNDROME
Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type III. Patient die (median 40 yrs) of vascular complications. There is no treatment.
- Trial name
- NCT00190411
- Testing
- celiprolol, Control
- Volunteers
- 54 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Expanded Access Program for Selinexor
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma
- Trial name
- KEAP (NCT07215832)
- Testing
- selinexor
- Sponsor
- Karyopharm Therapeutics Inc
Multiple Myeloma
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma.
- Trial name
- NCT01827137
- Testing
- Galinpepimut-S, GM-CSF, Montanide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sellas Life Sciences Group
Anticoagulant
Determinants of Oral Anticoagulants' Activity
The primary objective of the present study is to determine the clinical, biological and genetic determinants of the anticoagulant activity in patients treated with either anti-IIa or anti Xa oral anticoagulants.
- Trial name
- ANTIGOAG (NCT03172546)
- Testing
- PK-PD genetic polymorphisms
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room
The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room.
- Trial name
- Step down ward (NCT06286241)
- Volunteers
- 344 people
- Sponsor
- Siriraj Hospital
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Nipple Discharge
A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.
This is a prospective, single-center diagnostic study testing whether a new, minimally invasive analysis of nipple fluid can distinguish benign from malignant causes of pathologic nipple discharge.
- Trial name
- NCT07250204
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hubei Cancer Hospital
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Multiple Myeloma, Acute Renal Failure
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
Background:Plasma exchange has been suggested to be of theoretical benefit in the treatment of acute renal failure at the onset of multiple myeloma. Two small-randomized trials provide conflicting evidence.
- Trial name
- NCT00120263
- Testing
- Plasma Exchange
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- London Health Sciences Centre
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Dengue Fever, Dengue Hemorrhagic Fever
Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients
This clinical trial seeks to assess the effectiveness of fresh frozen plasma (FFP) in the treatment of thrombocytopenia in individuals with dengue.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
- Trial name
- EFFP-TDP (NCT06642493)
- Testing
- Fresh frozen plasma
- Where
- Bangladesh
- Volunteers
- 300 people
- Sponsor
- Sheikh Hasina National Institute of Burn and Plastic Surgery
Multiple Myeloma, Renal Impairment
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
This is an investigator-initiated (IIS), phase 2, prospective, open-label, multinational study, designed to be conducted in approximately 14 sites.
- Conditions
- Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type
- Trial name
- NCT05298683
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 6 sites in Greece
- Volunteers
- 108 people
- Sponsor
- Hellenic Society of Hematology
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Ehlers-Danlos Syndrome (EDS)
Impact of Ehlers-Danlos Syndrome on Gynaecological Health
Dysmenorrhea is a common problem in gynaecology, significantly impacting patients' quality of life. Ehlers-Danlos syndrome (EDS) is associated with joint hypermobility, tissue fragility and chronic pain.
- Trial name
- GYNESED (NCT07151274)
- Where
- France
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Melphalan in Patients With Neoplastic Meningitis
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of melphalan in patients with persistent or recurrent…
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00002750
- Testing
- melphalan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Cystitis, Bladder Diseases
Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
The goal of this clinical research study is to learn how the body absorbs and processes 1 dose of cidofovir that is given directly into the bladder, in patients with a viral infection that is causing bleeding from the bladder.
- Trial name
- NCT00956176
- Testing
- Cidofovir
- Sponsor
- M.D. Anderson Cancer Center